company background image
EBS

Emergent BioSolutionsNYSE:EBS Stock Report

Last Price

US$46.97

Market Cap

US$2.5b

7D

-10.1%

1Y

-56.2%

Updated

23 Jan, 2022

Data

Company Financials +
EBS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

EBS Stock Overview

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs).

Emergent BioSolutions Competitors

Celldex Therapeutics

NasdaqCM:CLDX

US$1.3b

Chimerix

NasdaqGM:CMRX

US$478.6m

Thermo Fisher Scientific

NYSE:TMO

US$228.7b

Sanofi

ENXTPA:SAN

€114.2b

Price History & Performance

Summary of all time highs, changes and price drops for Emergent BioSolutions
Historical stock prices
Current Share PriceUS$46.97
52 Week HighUS$127.20
52 Week LowUS$29.88
Beta0.93
1 Month Change3.19%
3 Month Change-7.65%
1 Year Change-56.15%
3 Year Change-21.74%
5 Year Change55.79%
Change since IPO301.45%

Recent News & Updates

Jan 20
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet?

Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Nov 16

Emergent BioSolutions: Rapid-Return Trade With More Legs

The modification/loss of a contract coupled with a weak earnings report sent the stock tumbling 40%. We jumped on this overreaction for a quick gain, but now see the stock rallying further into 2022 on some bullish developments. The company is anticipating a significant top-line ramp up in 2023 and 2024.

Shareholder Returns

EBSUS BiotechsUS Market
7D-10.1%-7.4%-6.1%
1Y-56.2%-22.0%4.2%

Return vs Industry: EBS underperformed the US Biotechs industry which returned -22% over the past year.

Return vs Market: EBS underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is EBS's price volatile compared to industry and market?
EBS volatility
EBS Average Weekly Movement13.2%
Biotechs Industry Average Movement10.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: EBS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: EBS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19982,200Bob Kramerhttps://www.emergentbiosolutions.com

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company’s products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine.

Emergent BioSolutions Fundamentals Summary

How do Emergent BioSolutions's earnings and revenue compare to its market cap?
EBS fundamental statistics
Market CapUS$2.53b
Earnings (TTM)US$227.00m
Revenue (TTM)US$1.65b

11.1x

P/E Ratio

1.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EBS income statement (TTM)
RevenueUS$1.65b
Cost of RevenueUS$913.50m
Gross ProfitUS$739.00m
ExpensesUS$512.00m
EarningsUS$227.00m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)4.22
Gross Margin44.72%
Net Profit Margin13.74%
Debt/Equity Ratio56.4%

How did EBS perform over the long term?

See historical performance and comparison

Valuation

Is Emergent BioSolutions undervalued compared to its fair value and its price relative to the market?

39.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EBS ($46.97) is trading below our estimate of fair value ($78.04)

Significantly Below Fair Value: EBS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: EBS is good value based on its PE Ratio (11.1x) compared to the US Biotechs industry average (23.1x).

PE vs Market: EBS is good value based on its PE Ratio (11.1x) compared to the US market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: EBS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: EBS is good value based on its PB Ratio (1.7x) compared to the US Biotechs industry average (1.9x).


Future Growth

How is Emergent BioSolutions forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-4.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EBS's earnings are forecast to decline over the next 3 years (-4.5% per year).

Earnings vs Market: EBS's earnings are forecast to decline over the next 3 years (-4.5% per year).

High Growth Earnings: EBS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: EBS's revenue is expected to decline over the next 3 years (-7.4% per year).

High Growth Revenue: EBS's revenue is forecast to decline over the next 3 years (-7.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EBS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Emergent BioSolutions performed over the past 5 years?

36.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EBS has high quality earnings.

Growing Profit Margin: EBS's current net profit margins (13.7%) are higher than last year (12.5%).


Past Earnings Growth Analysis

Earnings Trend: EBS's earnings have grown significantly by 36.7% per year over the past 5 years.

Accelerating Growth: EBS's earnings growth over the past year (36.3%) is below its 5-year average (36.7% per year).

Earnings vs Industry: EBS earnings growth over the past year (36.3%) exceeded the Biotechs industry 11%.


Return on Equity

High ROE: EBS's Return on Equity (14.9%) is considered low.


Financial Health

How is Emergent BioSolutions's financial position?


Financial Position Analysis

Short Term Liabilities: EBS's short term assets ($1.1B) exceed its short term liabilities ($365.4M).

Long Term Liabilities: EBS's short term assets ($1.1B) exceed its long term liabilities ($979.4M).


Debt to Equity History and Analysis

Debt Level: EBS's net debt to equity ratio (29.9%) is considered satisfactory.

Reducing Debt: EBS's debt to equity ratio has increased from 48.9% to 56.4% over the past 5 years.

Debt Coverage: EBS's debt is well covered by operating cash flow (27.6%).

Interest Coverage: EBS's interest payments on its debt are well covered by EBIT (9.8x coverage).


Balance Sheet


Dividend

What is Emergent BioSolutions's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EBS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EBS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EBS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EBS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EBS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Bob Kramer (64 yo)

3.83yrs

Tenure

US$5,569,978

Compensation

Mr. Robert G. Kramer., also known as Bob, has been President at Emergent BioSolutions Inc. since March 26, 2018 and has been its Chief Executive Officer and Director since April 01, 2019. Mr. Kramer was Ch...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD5.57M) is about average for companies of similar size in the US market ($USD5.29M).

Compensation vs Earnings: Bob's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: EBS's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: EBS's board of directors are considered experienced (8.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: EBS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Emergent BioSolutions Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Emergent BioSolutions Inc.
  • Ticker: EBS
  • Exchange: NYSE
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.527b
  • Shares outstanding: 53.80m
  • Website: https://www.emergentbiosolutions.com

Number of Employees


Location

  • Emergent BioSolutions Inc.
  • 400 Professional Drive
  • Suite 400
  • Gaithersburg
  • Maryland
  • 20879
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:08
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.